Warning: fopen(/home/virtual/enm-kes/journal/upload/ip_log/ip_log_2024-11.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 100 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 101
1Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea.
2Dreampharma Corp., Seoul, Korea.
3Department of Endocrinology and Metabolism, Keimyung University School of Medicine, Daegu, Korea.
4Department of Endocrinology and Metabolism, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
5Division of Endocrinology and Metabolism, Department of Internal Medicine, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, Korea.
6Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
7Division of Endocrinology and Metabolism, Department of Internal Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea.
8Divison of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
9Department of Internal Medicine, Endocrine Research Institute, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
10Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul, Korea.
11Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea.
12Department of Internal Medicine, Inje University College of Medicine, Busan, Korea.
13Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.
14Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon, Korea.
15Division of Endocrinology and Metabolism, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Korea.
16Department of Endocrinology and Metabolism, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.
17Department of Endocrinology and Metabolism, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Copyright © 2015 Korean Endocrine Society
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICTS OF INTEREST: This study was supported by Dreampharma Corp., of Seoul, Korea.
Values are expressed as mean±SD or number (%).
IBN+, the group which received a once-monthly pill containing 150 mg ibandronate and 24,000 IU cholecalciferol; IBN, the group which received a once-monthly pill containing 150 mg ibandronate; NS, not significant; BMD, bone mineral density; 25(OH)D, 25-hydroxyvitamin D; PTH, parathyroid hormone; BSAP, bone-specific alkaline phosphatase; CTX, C-telopeptide of type 1 collagen.
Values are expressed as mean±SD.
25(OH)D, 25-hydroxyvitamin D; IBN+, the group which received a once-monthly pill containing 150 mg ibandronate and 24,000 IU cholecalciferol; IBN, the group which received a once-monthly pill containing 150 mg ibandronate; NS, not significant; CTX, C-telopeptide of type 1 collagen; BSAP, bone-specific alkaline phosphatase; PTH, parathyroid hormone.
aWilcoxon's rank sum test; bWilcoxon's signed rank test; ct test; dPaired t test.
Values are expressed as mean±SD.
25(OH)D, 25-hydroxyvitamin D; CTX, C-telopeptide of type 1 collagen; IBN+, the group which received a once-monthly pill containing 150 mg ibandronate and 24,000 IU cholecalciferol; IBN, the group which received a once-monthly pill containing 150 mg ibandronate; NS, not significant.
at test; bWilcoxon's rank sum test; cPaired t test; dWilcoxon's signed rank test.
Characteristic | IBN+ (n=101) | IBN (n=98) | P value |
---|---|---|---|
Age, yr | 64.0±7.0 | 64.0±7.0 | NS |
Height, cm | 153.9±5.1 | 154.0±5.3 | NS |
Weight, kg | 55.2±7.7 | 56.5±8.3 | NS |
Alcohol history | NS | ||
Non | 81 (80.2) | 85 (86.7) | |
Quit | 13 (12.9) | 11 (11.2) | |
Drinking | 7 (6.9) | 2 (2.1) | |
Smoking history | NS | ||
Non | 99 (98.0) | 96 (98.0) | |
Smoking | 2 (2.0) | 2 (2.0) | |
BMD | NS | ||
-2.5<T-score≤-1.0 | 12 (11.9) | 12 (12.2) | |
T-score ≤-2.5 | 89 (88.1) | 86 (87.8) | |
25(OH)D, ng/mL | 21.04±10.42 | 20.55±9.25 | NS |
<20 | 51 (53.1) | 57 (60.0) | NS |
≥20 | 45 (46.9) | 38 (40.0) | |
PTH, ng/L | 39.9±13.4 | 39.0±12.6 | NS |
Calcium, mg/dL | 9.07±0.37 | 9.01±0.39 | NS |
Phosphorus, mg/dL | 3.91±0.40 | 3.88±0.43 | NS |
Bone markers | |||
BSAP, U/L | 35.6±11.5 | 36.8±12.6 | NS |
CTX, ng/mL | 0.39±0.18 | 0.37±0.18 | NS |
Variable | IBN+ | IBN | P value |
---|---|---|---|
25(OH)D, ng/mL | |||
Baseline | 21.0±10.4 | 20.6±9.3 | NSa |
16-wk | 25.3±9.9 | 17.4±9.2 | <0.001a |
P value | <0.001b | <0.001b | |
CTX, ng/mL | |||
Baseline | 0.39±0.18 | 0.37±0.18 | NSa |
16-wk | 0.19±0.13 | 0.20±0.15 | NSa |
P value | <0.001b | <0.001b | |
BSAP, U/L | |||
Baseline | 35.6±11.5 | 36.8±12.6 | NSa |
16-wk | 24.8±7.8 | 13.9±4.5 | NSa |
P value | <0.001b | <0.001b | |
PTH, ng/L | |||
Baseline | 39.9±13.4 | 39.0±12.6 | NSa |
16-wk | 42.6±15.5 | 45.9±17.0 | NSa |
P value | <0.05b | <0.001b | |
Calcium, mg/dL | |||
Baseline | 9.1±0.4 | 9.0±0.4 | NSc |
16-wk | 8.8±0.5 | 8.7±0.5 | NSa |
P value | <0.001d | <0.001b | |
Phosphorous, mg/dL | |||
Baseline | 3.9±0.4 | 3.9±0.4 | NSc |
16-wk | 3.6±0.5 | 3.7±0.5 | NSa |
P value | <0.001d | <0.001b |
Variable | 25(OH)D, ng/mL | CTX, ng/mL | ||||
---|---|---|---|---|---|---|
IBN+ | IBN | P value | IBN+ | IBN | P value | |
Baseline 25(OH)D, ng/mL | ||||||
<10 | ||||||
No. | 11 | 6 | 11 | 6 | ||
Baseline | 8.2±1.4 | 9.4±0.5 | <0.05a | 0.34±0.12 | 0.40±0.20 | NSa |
16-wk | 20.5±7.2 | 11.8±4.3 | <0.05a | 0.16±0.11 | 0.22±0.21 | NSb |
P value | <0.001c | NSc | <0.001c | NSc | ||
≥10 to <20 | ||||||
No. | 40 | 51 | 40 | 51 | ||
Baseline | 15.1±2.5 | 15.3±2.9 | NSb | 0.41±0.20 | 0.36±0.18 | NSb |
16-wk | 23.4±9.3 | 14.0±4.5 | <0.001b | 0.22±0.17 | 0.20±0.16 | NSb |
P value | <0.001d | NSc | <0.001c | <0.001c | ||
≥20 | ||||||
No. | 45 | 38 | 45 | 38 | ||
Baseline | 29.5±9.1 | 29.4±8.1 | NSb | 0.38±0.18 | 0.37±0.18 | NSb |
16-wk | 28.2±10.2 | 22.9±11.5 | <0.05b | 0.18±0.10 | 0.21±0.13 | NSb |
P value | NSd | <0.001c | <0.001c | <0.001c |
Values are expressed as mean±SD or number (%). IBN+, the group which received a once-monthly pill containing 150 mg ibandronate and 24,000 IU cholecalciferol; IBN, the group which received a once-monthly pill containing 150 mg ibandronate; NS, not significant; BMD, bone mineral density; 25(OH)D, 25-hydroxyvitamin D; PTH, parathyroid hormone; BSAP, bone-specific alkaline phosphatase; CTX, C-telopeptide of type 1 collagen.
Values are expressed as mean±SD. 25(OH)D, 25-hydroxyvitamin D; IBN+, the group which received a once-monthly pill containing 150 mg ibandronate and 24,000 IU cholecalciferol; IBN, the group which received a once-monthly pill containing 150 mg ibandronate; NS, not significant; CTX, C-telopeptide of type 1 collagen; BSAP, bone-specific alkaline phosphatase; PTH, parathyroid hormone. aWilcoxon's rank sum test; bWilcoxon's signed rank test; c
Values are expressed as mean±SD. 25(OH)D, 25-hydroxyvitamin D; CTX, C-telopeptide of type 1 collagen; IBN+, the group which received a once-monthly pill containing 150 mg ibandronate and 24,000 IU cholecalciferol; IBN, the group which received a once-monthly pill containing 150 mg ibandronate; NS, not significant. a